Page 37 - Mobile Android News Today

Functional and structural glaucoma severity was associated with impaired intrinsically photosensitive retinal ganglion cell function, according to a study published in Investigative Ophthalmology and Visual Science.

SALT LAKE CITY — Ibrutinib appeared safe and effective for children with previously untreated or relapsed/refractory chronic graft-versus-host disease, according to study results. Paul A. Carpenter, MD, professor at Fred Hutchinson Cancer Research Center, presented the results at Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR.

The FDA approved mavacamten for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy, the first cardiac myosin inhibitor to be permitted for use in the United States, Bristol Myers Squibb announced.Mavacamten (Camzyos, Bristol Myers Squibb) is the first and only FDA-approved allosteric and reversible inhibitor selective for cardiac myosin that targets the underlying

Erythematotelangiectatic and papulopustular rosacea were found to be the chronic skin condition’s most common subtypes, according to a systematic review and meta-analysis. “Four distinct rosacea subtypes have traditionally been recognized, but the frequency of these subtypes among patients with rosacea remains unknown,” Yousef A. Barakji, MS, of the department of dermatology at

Qualcomm severely beats Wall Street predictions with record FY Q222 earnings.

Families and clinicians alike often have questions about care when it comes to food allergies, from understanding cutting-edge treatments such as oral immunotherapy to addressing psychosocial burdens such as phobias and bullying. Answers and more can be found at the Food Allergy Conference for Education & Science (FACES) from June 10 to 11 in Chicago, according to its host, the Center for

The FDA granted orphan drug designation to ALLO-605, a chimeric antigen receptor T-cell therapy for adults with relapsed or refractory multiple myeloma.ALLO-605 (Allogene Therapeutics) is an allogeneic, gene-edited CAR T-cell therapy that targets the B-cell maturation antigen (BCMA) on the surface of cancer cells. The investigational agent was previously given fast track designation by the FDA.

DALLAS — Multiple factors predicted improved survival among patients with head and neck or salivary gland cancers treated with pembrolizumab plus vorinostat, according to prospective study results.Patients with lower pretreatment neutrophils and neutrophil-to-lymphocyte ratios — as well as those with more pretreatment lymphocytes and T helper cells — achieved longer OS and PFS,

The FDA has approved VIVJOA — the first medication for recurrent vulvovaginal candidiasis — for use in permanently infertile and postmenopausal women, according to a Mycovia Pharmaceuticals press release.

Influenza vaccination coverage in adults with early rheumatoid arthritis in Canada remains “suboptimal,” according to data published in ACR Open Rheumatology.